Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.

Blood - 10 Dec 2015

Verger Emmanuelle, Cassinat Bruno, Chauveau Aurélie, Dosquet Christine, Giraudier Stephane, Schlageter Marie-Hélène, Ianotto Jean-Christophe, Yassin Mohammed A, Al-Dewik Nader, Carillo Serge, Legouffe Eric, Ugo Valerie, Chomienne Christine, Kiladjian Jean-Jacques

Abstract excerpt

Myeloproliferative neoplasms are clonal disorders characterized by the presence of several gene mutations associated with particular hematologic parameters, clinical evolution, and prognosis. Few therapeutic options are available, among which interferon α (IFNα) presents interesting properties like the ability to induce hematologic responses (HRs) and molecular responses (MRs) in patients with JAK2 mutation. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aspirin
Share to Calreticulin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Clonal Evolution

Share to Dioxygenases

Share to Hydroxyurea

Share to Polyethylene Glycols

Share to Remission Induction

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 26486786
DOI: 10.1182/blood-2015-07-659060

Genes

CALR
ASXL1
IDH2
JAK2
TET2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.PMID 26486786Read ↗

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.Semantic proximity Read ↗

Pegylated interferon: the who, why, and howSemantic proximity Read ↗

Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.Semantic proximity Read ↗

Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Interferon alfa therapy in CALR-mutated essential thrombocythemia.Semantic proximity Read ↗

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.Semantic proximity Read ↗

Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression.Semantic proximity Read ↗

Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat.Semantic proximity Read ↗

Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.Semantic proximity Read ↗

Anagrelide and Mutational Status in Essential Thrombocythemia.Semantic proximity Read ↗

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.